Central Sleep Apnea Treatment Guidelines Updated
- DETROIT, MI - November 21, 2023 - The American Academy of Sleep Medicine (AASM) has released updated clinical practice guidelines for the treatment of central sleep apnea (CSA),...
- What: Updated clinical practice guidelines for Central Sleep Apnea (CSA) treatment.
- Central sleep apnea differs from the more common obstructive sleep apnea.
New Guidelines Offer Updated Approach to central Sleep Apnea Treatment
Table of Contents
DETROIT, MI – November 21, 2023 – The American Academy of Sleep Medicine (AASM) has released updated clinical practice guidelines for the treatment of central sleep apnea (CSA), reflecting new research and therapeutic options. The guidelines, published as an accepted paper in the Journal of Clinical Sleep Medicine, emphasize individualized patient care and prioritize quality of life improvements over simply eliminating breathing events. This update builds upon previous AASM parameters from 2012 and 2016, incorporating evidence from studies on adaptive servo ventilation (ASV) and the emerging therapy of transvenous phrenic nerve stimulation (TPNS).
Central sleep apnea differs from the more common obstructive sleep apnea. It’s characterized by a disruption in breathing effort and airflow during sleep, frequently enough linked to underlying conditions like heart failure, existing obstructive sleep apnea, or opioid use. The AASM guidelines acknowledge the varied causes of CSA and stress the importance of addressing the root issue when selecting treatment.
conditional recommendations & Treatment Options
All nine clinical recommendations within the guideline are classified as “conditional.” This signifies that while supported by evidence, clinical judgment and patient preferences are crucial in determining the best course of action. The guidelines support six treatment options, tailored to the specific cause of the CSA:
* Continuous Positive Airway Pressure (CPAP): A common treatment, delivering constant air pressure.
* Bilevel positive Airway Pressure with a Backup Rate (BiPAP): Provides different pressures for inhalation and exhalation, with a set backup breathing rate.
* Adaptive Servo Ventilation (ASV): Adjusts pressure support based on the patient’s breathing pattern. Caution advised for heart failure patients – see below.
* Low-Flow Oxygen: Supplemental oxygen to improve blood oxygen levels.
* Oral Acetazolamide: A medication that can stimulate breathing.
* Transvenous Phrenic Nerve stimulation (TPNS): An implantable device that stimulates the phrenic nerve to regulate breathing.
- drjenniferchen
These updated guidelines represent a important step forward in CSA management. The shift towards individualized care is particularly important, as CSA is rarely a standalone condition. The ‘conditional’ recommendation designation is also a pragmatic approach,acknowledging the complexities of the disease and the need for clinicians to weigh evidence alongside patient-specific factors. The caution surrounding ASV in heart failure patients is crucial, reflecting concerns raised by recent research. the inclusion of TPNS as a viable option, albeit with caveats, highlights the evolving landscape of CSA treatment.
Adaptive Servo Ventilation (ASV) & Heart Failure
While ASV received a conditional recommendation for CSA with multiple causes, the guidelines highlight concerns regarding its use in patients with heart failure and reduced ejection fraction. A recent clinical trial raised questions about potential adverse effects in this population. Therefore, the AASM recommends that ASV treatment for these patients be limited to specialized centers with experience and require close monitoring.
Transvenous Phrenic Nerve Stimulation (TPNS): A New Option
The guidelines include a new conditional recommendation for TPNS for primary CSA and CSA stemming from heart failure. Approved by the FDA in 2017, TPNS involves an implantable device that continuously monitors and stabilizes breathing by stimulating the phrenic nerve. However, the guidelines acknowledge the limitations of TPNS, including its invasive nature, limited accessibility, and high cost.
Understanding the Prevalence & Impact of CSA
While obstructive sleep apnea is more widely recognized, central sleep apnea affects a significant number of individuals. The exact prevalence is challenging to determine due to diagnostic challenges, but it is commonly found in individuals with specific medical conditions.
| Condition | Estimated CSA Prevalence |
|---|---|
| Heart Failure | 20-50% |
| Stroke | 10-30% |
| Opioid Use | Variable,frequently enough high |
| Obstructive Sleep Apnea | 5-10% (overlap syndrome) |
Data based on various studies; prevalence can vary.
“Central sleep apnea is a complex form of sleep-disordered breathing that requires individualized, patient-centered care,” explains Dr. M.Safwan Badr, lead author of the guideline. “It is essential for the